Lheureux S, Oaknin A, Garg S, Bruce JP, et al. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clin Cancer Res 2020 May 22. pii: 1078-0432.CCR-19-4121.
PMID: 32444417